Get the Stockscreener App
1.38
0.73%
0.010
After Hours:
1.35
-0.03
-2.17%
Pasithea Therapeutics Corp stock is traded at $1.38, with a volume of 113.96K.
It is up +0.73% in the last 24 hours and up +22.12% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$1.37
Open:
$1.44
24h Volume:
113.96K
Relative Volume:
0.04
Market Cap:
$3.19M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0992
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
-13.75%
1M Performance:
+22.12%
6M Performance:
-65.41%
1Y Performance:
-80.70%
1-Day Range:
$1.33
$1.4739
1-Week Range:
$1.13
$1.70
52-Week Range:
$0.95
$7.69
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
1.38 | 3.19M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing C - Asianet Newsable
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial By Investing.com - Investing.com South Africa
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial - marketscreener.com
Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga
KTTA’s Unexpected Surge: Analysis of Recent Performance - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial - Investing.com
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer - MarketScreener
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewswire
Pasithea Therapeutics Corp. Announces Positive Safety Review Committee Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - marketscreener.com
3 Reasons to Avoid HEES and 1 Stock to Buy Instead - The Globe and Mail
Groundbreaking Cancer Trial: New Drug Shows Perfect Safety Record, Outperforming Competitors - Stock Titan
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update - Yahoo Finance
U.S. Exosomes Market to Surge from $101 Million to $1,917.72 Million by 2034 | Towards Healthcare - Yahoo Finance
60 Degrees and Yale to progress tafenoquin for babesiosis - Yahoo Finance
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Yahoo Finance
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - Yahoo Finance
If You Invested $10K In PotlatchDeltic Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Yahoo Finance
Why Viking Holdings Ltd. (VIK) Surged On Tuesday? - Yahoo Finance
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease - Yahoo Finance
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - Yahoo Finance
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - Yahoo Finance
Zevra Therapeutics Files Preliminary Proxy - Yahoo Finance
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference - The Manila Times
Pasithea Therapeutics to Present at 2025 CAGLA NeauxCancer Conference on Next-Generation MEK Inhibitor PAS-004 - Nasdaq
New Clinical Data: Pasithea's Novel Cancer Drug Shows Promise in Phase 1 Trial - Stock Titan
Down 42%, Should You Buy Tesla Stock on the Dip? - The Globe and Mail
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer - Yahoo Finance
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy - Yahoo Finance
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer - Yahoo Finance
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Yahoo Finance
KTTA stock touches 52-week low at $1.12 amid market challenges - Investing.com India
KTTA stock touches 52-week low at $1.12 amid market challenges By Investing.com - Investing.com South Africa
Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
AvePoint Announces Fourth Quarter and Full Year 2024 Financial Results - The Globe and Mail
Super Micro stock rallies after meeting Nasdaq deadline to avoid delisting - Yahoo Finance
KTTA stock touches 52-week low at $1.24 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $1.24 amid market challenges By Investing.com - Investing.com South Africa
Pasithea's PAS-004 advances in cancer trial with no toxicities - MSN
Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ... - Yahoo Finance
AvePointHas An A-Client List - The Globe and Mail
KTTA stock touches 52-week low at $1.32 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update - Defense World
Pasithea Therapeutics Corp (KTTA) Stock: A Study of the Market Performance - The News Heater
An analyst sees good growth prospects for Pasithea Therapeutics Corp (KTTA) - SETE News
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):